Month: April 2021

Ceapro Inc. (CRPOF)(CZO:CA) – Announces Successful Completion of Collaborative Research and Development Program with University of Alberta

Posted on by Admin


Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta

 

– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –

– New PGX-based products developed under the collaboration paves the way for commercial scale production of new chemical complexes and innovative delivery systems –

– Potential for applications in personal care, functional food, dietary supplement and pharmaceuticals –

– Findings to be presented at the upcoming 18 th European Meeting on Supercritical Fluids –

EDMONTON, Alberta, April 08, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of its long-term research project with Professor Dr. Feral Temelli at the University of Alberta (UofA). Based on the successful results of the project, Ceapro will expand the utilization of the PGX Technology and generate innovative high-value ingredients with a competitive advantage, targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals.

The collaborative project titled “ PGX technology for drying of biopolymers and their impregnation with bioactives ” was initiated in June 2017 and leveraged funding with the Collaborative Research and Development (CRD) grant project from the Natural Sciences and Engineering Research Council of Canada (NSERC). The goal of the project was to expand the array of PGX-processed polymers impregnated with bioactives based on a solid understanding of their behavior under the PGX processing conditions and the interactions between them.

“This project allowed for the screening of various compounds and the retention of the most promising ones with the best marketing potential. With these important findings, we have established an expanded PGX-based product pipeline further supporting the investment decision for the commercial scale up of the PGX Technology for the processing of oat beta glucan, yeast beta glucan and alginate. These first three products offer potential benefits either as stand-alone products or as carrier for other bioactives. We are very grateful to Professor Dr. Feral Temelli, her research team at the UofA, and Ceapro’s research team for the success in this extensive collaborative research project,” commented Mr. Gilles Gagnon, President and Chief Executive Officer of Ceapro.

Results from this NSERC-CRD project demonstrated for the first time that Ceapro’s PGX Technology could be used to not only dry and purify polysaccharides like beta glucan, but also proteins and peptides, which could then be impregnated with valuable bioactives. Additionally, by leveraging the PGX Technology, the research team was able to generate unique composites known as exfoliated nanocomposites, made of homogenously intertwined polymers (e.g. polysaccharides, proteins, enzymes and gums) with remarkable new properties. This project also greatly contributed to the development of new processing approaches using the PGX Technology, especially for the development of new delivery systems even making the dispersions of hydrophobic bioactives in water stable.

“Over the course of this project, significant inroads were made into a completely new and promising field – the simultaneous drying, purification and functionalization of proteins, peptides, and enzymes,” said Dr. Paul Moquin, Director Scientific Affairs and New Business Development at Ceapro. “Researchers made unique alginate-protein composites made of homogenously intertwined polymers with remarkable new properties. Although it is early to totally capture the full impact that such findings will have on the development of future products, we expect that it will be disruptive to many economic sectors.”

Considerable resources were deployed during this project to study and characterize the PGX material, novel composites, and new delivery systems. Among all the work that was conducted, enhanced release kinetics of these hydrophobic bioactives in simulated gastrointestinal conditions was demonstrated, which is an indication of their potential increased bioavailability that can lead to improved health benefits. Results allow the selection of the best polymer as the carrier to generate optimal delivery systems for targeted applications including functional food, dietary supplement, personal care, cosmetic and drug applications.

“We are very happy to successfully complete this very ambitious project, generating a lot of new information, and paving the way for new opportunities and future applications of the PGX Technology,” said Professor Dr. Feral Temelli from the Department of Agricultural, Food & Nutritional Science of the University of Alberta. “It was a major collaborative effort between our teams at the University of Alberta and Ceapro. Based on the training received at the UofA throughout this project, two of my team members were hired by Ceapro and it is wonderful that they continue to contribute to the growth of the PGX Technology. I really appreciate the financial support of NSERC-CRD program and Ceapro for this major project.”

As a result of this collaborative work, Ceapro has greatly expanded its portfolio of innovative bioactive ingredients and delivery systems, and has garnered international attention, both in the industrial sector and the scientific community. The Company expects additional findings from this project to be published in peer-reviewed journals and scientific conferences, including three abstract presentations that have been accepted at the 18 th European Meeting on Supercritical Fluids (EMSF) being held virtually May 4-6, 2021. One of the abstracts will be presented as a keynote address by Dr. Feral Temelli.

About Pressurized Gas eXpanded Liquid Technology (PGX)

Ceapro’s patented Pressurized Gas eXpanded (PGX) technology is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, fine-structured, open-porous polymer structures and novel biocomposites. PGX is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers. It can make ultra-light, highly porous polymer structures on a continuous basis, which is not possible using today’s conventional technologies. PGX was invented by Dr. Feral Temelli from the Department of Agricultural, Food & Nutritional Science of the University of Alberta (U of A) along with Dr. Bernhard Seifried, now Senior Director of Research and Technology at Ceapro. The license from U of A provides Ceapro with exclusive worldwide rights in all industrial applications.

About University of Alberta

The University of Alberta in Edmonton is one of Canada’s top teaching and research universities, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering, and health sciences. Home to more than 38,000 students and 15,000 faculty and staff, the university has an annual budget of $1.9 billion and attracts more than $500 million in sponsored research revenue. The U of A offers close to 900 rigorous undergraduate, graduate, and professional programs in 18 faculties on five campuses-including one rural and one francophone campus. The university has more than 275,000 alumni worldwide. The university and its people remain dedicated to the promise made in 1908 by founding President Henry Marshall Tory that knowledge shall be used for “uplifting the whole people.”

About Natural Sciences and Engineering Research Council of Canada (NSERC)

The NSERC, through grants, fellowships and scholarships, promotes and supports research and research training in the natural sciences and engineering to develop talent, generate discoveries, and support innovation in pursuit of economic and social outcomes for Canadians

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company’s website at www.ceapro.com .

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Source: Ceapro Inc.

electroCore Inc. (ECOR) – Announces Top Line Results From SAVIOR-1 Study

Posted on by Admin


electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

 

ROCKAWAY, NJ, 
April 08, 2021 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the top-line results from the SAVIOR-1 study, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire in patients admitted to the hospital for treatment of COVID-19 between 
April 2020 and 
February 2021. This study was an investigator-initiated trial conducted at the Hospital Clínico Universitario de 
Valencia, Spain.

The SAVIOR-1 study enrolled 110 patients over 18 years of age. A total of 97 patients (47 treatment subjects and 50 control subjects) provided baseline demographic and medical history data. The study was designed to evaluate the safety and feasibility of nVNS in addition to the current standard of care in patients hospitalized with active SARS-CoV-2 infection. This pilot study also assessed the incidence of relevant clinical events and changes in blood chemistry between the group treated with nVNS in addition to the standard of care at the time of admission, compared with standard of care alone.

The patients’ clinical and biochemical endpoints were measured over their first five days of therapy and the adjusted means were compared. It was noted that the post-randomized assessment of severity of condition resulted in a 3.5 to 1 bias with more severe patients in the treatment arm.  With respect to the clinical endpoint of oxygen saturation, the nVNS treated group showed a modest, but not significant improvement. Among the biomarkers evaluated, the adjusted mean decrease in C-Reactive Protein (CRP) from baseline was significantly greater in the nVNS treated group (-59.08 vs. -27.83; p<0.01). Trends toward significance were also observed for decreases in the treatment group for procalcitonin (-0.11 vs. -0.05; p= 0.07) and d-dimer (-277.53 vs. 1264.37; p=0.08). Increased levels of CRP, procalcitonin and d-dimer have all been reported to be associated with more severe disease. The lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms. Other biochemical measures also favored the treatment group but did not achieve significance.

nVNS was well tolerated with no major device related adverse events and the therapy was administered three times daily on the majority of patients as outlined in the study protocol. Full data from the study, including cytokine levels which are pending final lab results, will be submitted to a peer reviewed journal later this year.

The principal investigator of the study, Dr.  Carlos Tornero, Head of the 
Department of Anesthesiology, Resuscitation and Pain Therapeutics of the Hospital Clínico Universitario de 
Valencia, Spain, commented, “We are very pleased to have successfully completed the SAVIOR-1 study despite the challenges of executing a trial of a novel neuromodulation treatment during  a pandemic, and the rapidly changing standard of care in COVID-19 patients. These top line results suggest that nVNS may contribute to our efforts in combating the on-going disease process through a more rapid recovery in some of the biomarkers that are typically associated with a more severe prognosis.”

“The ability of nVNS to potentially affect the progression of COVID-19 in these hospitalized patients is encouraging.” said Dr.  Peter Staats, Chief Medical Officer of electroCore. “As the pandemic evolves, we believe that nVNS could be a viable treatment for patients to possibly help decrease their symptoms early in the disease. Although a minority of the subjects in the study were classified as severe, the randomization process apportioned more than 75% of the severe population into the treatment arm, which may have impacted the top line results.”

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM
gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric
    • Patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

The U.S. FDA has cleared the gammaCore Sapphire CV device under an emergency use authorization for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved pharmacologic therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, using noninvasive vagus nerve stimulation (nVNS) on either side of the patient’s neck.

gammaCore Sapphire CV has been authorized only for the duration of the statement that circumstances exist that warrant authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbbb-3(b)(1), until the authorization is terminated or revoked.

More information can be found at:

Letter of authorization: https://www.fda.gov/media/139967/download

Fact sheet for healthcare workers: https://www.fda.gov/media/139968/download

Patient information sheet: https://www.fda.gov/media/139969/download

Instructions for use of gammaCore: https://www.fda.gov/media/139970/download

Forward-looking statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the 
SEC, available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
ECOR@cg.capital

or

Media Contact:
Summer Diaz
electroCore
973-290-0097
summer.diaz@electrocore.com

Endeavor Silver (EXK) – Produces 1,048,100 oz Silver and 11,109 oz Gold for 1.9 Million oz Silver Equivalents in Q1 2021

Posted on by Admin

 


Endeavour Silver Produces 1,048,100 oz Silver and 11,109 oz Gold for 1.9 Million oz Silver Equivalents in Q1, 2021

 

VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) —
Endeavour Silver Corp. (TSX: EDR, NYSE: EXK) reports production of 1,048,100 silver ounces (oz) and 11,109 gold oz in Q1, 2021, for silver equivalent (AgEq) production of 1.9 million oz at an 80:1 silver:gold ratio. Silver production increased 22% and gold production increased 31% compared to Q1, 2020, due primarily to higher ore grades mined and processed.

2021 First Quarter Highlights

  • Consolidated
    Production on Plan:     Silver equivalent production at each mine is on track to meet or exceed 2021 production plans.
  • Guanacevi
    Production on Plan:     Higher silver and gold grades were partly offset by slightly lower throughput than planned during the quarter.
  • Bolanitos Ahead of Plan: Processed tonnes, gold grade and gold recoveries are ahead of plan, partly offset by slightly lower silver grades and recoveries compared to plan.
  • El Compas Ahead of Plan: Processed tonnes, and gold grade are ahead of plan, partly offset by slightly lower silver grade and lower gold recoveries compared to plan.
  • Metal Sales and
    Inventories:     Sold 623,379 oz silver and 10,663 oz gold, held 523,235 oz silver and 1,123 oz gold of bullion inventory and 6,582 oz silver and 566 oz gold in concentrate inventory. Management withheld metal from sale during the price correction over last two weeks of March and plans to sell the withheld metal inventory in anticipation of a precious metal prices rebound in Q2, 2021.
  • Signed Definitive
    Agreement to Sell the El Cubo Assets:     Advanced sale of the El Cubo mine in Guanajuato, Mexico to VanGold Mining Corp for $15 million in cash and share payments, with up to $3 million in contingent payments. The transaction is anticipated to close in April 2021.
  • Shares Included in Two Major Indices: The Company’s common shares were added to the S&P/TSX Composite Index and the NYSE Arca Gold Miners Index (GDX ETF) in March.
  • Announced Management Succession Plan: Bradford Cooke plans to step down as CEO and assume the role of Executive Chair of the Company following the AGM on May 12, 2021. Dan Dickson has been nominated to the role of CEO and Christine West has been nominated to become the CFO. Both Mr. Dickson and Ms. West have been key members of management for over 13 years and will lead the Company into its next phase of growth.

Bradford Cooke, Endeavour CEO, commented, “It is gratifying to see the Company firing on all cylinders, with the mining operations meeting or exceeding expectations and the development team advancing the Terronera project to drive the next phase of growth. I will look forward to supporting Dan and Christine in their new roles as they build a bigger and better Company.”

Mine Operations

Consolidated silver and gold production were both higher in Q1, 2021 compared to Q1, 2020 due to a significant increase in ore grades at Guanacevi and improved throughput and ore grades at Bolanitos.

Guanacevi silver and gold grades were higher compared to Q1, 2020 and well above plan. In February, unusually cold weather in northern Mexico resulted in power curtailments effecting mine and process plant production over a three-day period. In March, throughput was lower than initially planned as the refurbishment of the tailings filter presses impacted daily throughput. The plant throughput is expected to return to its 1200 tonnes per day capacity in April. Stockpiled ore inventory increased during the quarter as the mine output was on plan. With the higher metal prices, supplies of local third-party ores continued to supplement mine production, amounting to 10% of quarterly throughput, and contributed to the higher ore grades. Ore grades are expected to revert to plan in Q2, 2021 and for the remainder of the year.

Bolanitos and El Compas processed tonnes, and gold grade were all higher compared to Q1, 2020, partly offset by lower silver grades and both mines are slightly ahead of planned production. Settlement of El Compas concentrates resulted in lower recoveries during the quarter.

COVID-19 pandemic remains prevalent in Mexico, and at the Company’s business locations, process and protocols remain in place to ensure staff and workers as well as our communities remain as safe as possible.

Production Highlights for Q1, 2021

Q1 2021 Highlights

Three Months Ended March 31

2021

2020

% Change

Throughput (tonnes)

209,453

199,327

5%

Silver ounces produced

1,048,100

857,659

22%

Gold ounces produced

11,109

8,476

31%

Payable silver ounces produced

1,036,710

849,791

22%

Payable gold ounces produced

10,894

8,320

31%

Silver equivalent ounces produced(1)

1,936,820

1,535,739

26%

Silver ounces sold

623,379

665,500

(6%)

Gold ounces sold

10,663

7,454

43%

(1)    Silver
equivalent ounces calculated using 80 :1 ratio .

Production Tables for First Quarter, 2021 by Mine

Production

Tonnes

Tonnes

Grade

Grade

Recovery

Recovery

Silver

Gold

by
mine

Produced

per day

Ag gpt ( 1)

Au gpt ( 1)

Ag %

Au %

Oz

Oz

Guanaceví

88,632

974

369

1.05

87.3%

91.7%

918,217

2,743

Bolañitos

97,692

1,074

38

2.15

89.0%

91.5%

106,227

6,182

El Compas

23,129

254

47

4.12

67.7%

71.3%

23,656

2,184

Consolidated

209,453

2,302

179

1.90

86.9%

86.7%

1,048,100

11,109

(1)  gpt = grams per tonne

Release of First Quarter,
2021 Financial Results and Conference Call

The 2021 First Quarter Financial Results will be released before market on Tuesday, May 11, 2021 and a telephone conference call will be held the same day at 9:00am PT (12:00pm ET). To participate in the conference call, please dial the numbers below. No pass code is necessary.

Toll-free in Canada and the US: 1-800-319-4610
Local Vancouver: 604-638-5340
Outside of Canada and the US: +604-638-5340

A replay of the conference call will be available by dialing 1-800-319-6413 in Canada and the US (toll-free) or +604-638-9010 outside of Canada and the US. The required pass code is 6594#. The audio replay and a written transcript will be available on the Company’s website at www.edrsilver.com under the Investor Relations, Events section.

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer.  Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact Information:
Galina Meleger, Director, Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: gmeleger@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding the timing of suspension of
mining operations, Endeavour’s anticipated performance in 2021, including
production forecasts, cost estimates and metal price estimates, and the timing
and results of mine expansion and development and receipt of various permits.
The Company does not intend to and does not assume any obligation to update
such forward-looking statements or information, other than as required by
applicable law.

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, performance
or achievements of Endeavour and its operations to be materially different from
those expressed or implied by such statements. Such factors include, among
others, uncertainty of the ultimate impact of the COVID 19 pandemic on
operations, changes in national and local governments, legislation, taxation,
controls, regulations and political or economic developments in Canada and
Mexico; operating or technical difficulties in mineral exploration, development
and mining activities; risks and hazards of mineral exploration, development
and mining; metal prices; the speculative nature of mineral exploration and
development, risks in obtaining necessary licenses and permits, and challenges
to the Company’s title to properties; as well as those factors described in the
section “risk factors” contained in the Company’s most recent form 40F/Annual
Information Form filed with the S.E.C. and Canadian securities regulatory
authorities.

Forward-looking statements
are based on assumptions management believes to be reasonable, including but
not limited to: the continued operation of the Company’s mining operations ,the
impact of the COVID 19 pandemic on mining operations in Mexico generally, and
the Company’s operations specifically, no material adverse change in the market
price of commodities, mining operations will operate and the mining products
will be completed in accordance with management’s expectations and achieve
their stated production outcomes, resource and reserve estimates, metal prices,
and such other assumptions and factors as set out herein. Although the Company
has attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or
information, there may be other factors that cause results to be materially different
from those anticipated, described, estimated, assessed or intended. There can
be no assurance that any forward-looking statements or information will prove
to be accurate as actual results and future events could differ materially from
those anticipated in such statements or information. Accordingly, readers
should not place undue reliance on forward-looking statements or information.

Source: Endeavour Silver Corporation

The GEO Group, Inc. (GEO) – Suspends Dividend; Evaluating Corporate Structure

Posted on by Admin

Thursday, April 08, 2021

The GEO Group, Inc. (GEO)
Suspends Dividend; Evaluating Corporate Structure

With over 94,000 beds owned, leased or managed across its business lines and serving over 260,000 people daily, GEO is a leading provider of mission critical real estate to its governmental partners. The Company is the first fully integrated equity REIT specializing in the design, financing, development, and operation of secure facilities, processing centers, and community reentry centers in the U.S., Australia, South Africa, and the U.K.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Dividend Suspension. In a not so surprising move, GEO Group announced it is immediately suspending the quarterly dividend. The suspension eliminates approximately $30 million in quarterly dividend payments. Management expects to use the dividend savings and lowered capital expenditure plans to repay a minimum of $125-$150 million of net debt in 2021.

    Evaluating Corporate Structure.  The Company also announced it is undertaking an evaluation of the current REIT structure. The evaluation is expected to be completed in the fourth quarter of 2021. Obviously, uncertainty swirling around the current operating and the prosed increase in the corporate tax rate will both be important considerations …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Boomer Holdings (BOMH) – Provides Shareholder Update and Q1 Guidance With New Revenue and Profit Forecasts

Posted on by Admin

 


Boomer Provides Shareholder Update and Q1 Guidance With New Revenue and Profit Forecasts

 

LAS VEGAS, April 8, 2021 /PRNewswire/ — Boomer Holdings, Inc. (“Boomer” or the “Company”) (OTCQB: BOMH), an innovative Consumer Products Company specializing in a large variety of premium quality wellness and everyday use products under the Boomer brand name.  The Company provided a shareholder update on the Company’s operations in conjunction with its change of its fiscal year end to January 31.

The Company had a record quarter ending October 31, 2020 with revenue of $28.8 million and operating profits of $7.9 million.  The Company plans to announce the audited year end January 31, 2021 financials by early May 2021.

Mike Quaid, CEO of Boomer Naturals said: “While we are extremely proud to report our results and the accomplishments of the Boomer Naturals team over the past year, we are more excited for the growth that we hope to come in 2021. Boomer Naturals has taken its meteoric success over the last year and reinvented itself.  We are at the beginning of what I believe to be one of the great growth stories of 2021.”

Studies show that consumers are less willing to buy ‘Made in China’ items in the wake of the Coronavirus pandemic, which we believe will help fuel growth as all Boomer products are made in Vietnam or the USA. 1

The Company is preparing the launch of its proprietary marketplace: boomerstore.com which will allow the Company to expand its offering to its loyal group of over 200,000 online customers while expanding its already significant retail sales footprint.

“The first quarter of 2021 for Boomer has been focused on preparation to service the expected demand Boomer has created for the rest of the year,” said Mr. Quaid. “We have deployed our capital in a strategic manner and stand ready to reap the benefits in Q2 and beyond.”  

Boomerstore.com will provide new and already established consumers with direct access to Boomer Naturals three pillars of wellness and everyday use products: Protect, Defend and Enhance.

Protect

Boomer Naturals is already well known for the best-in-class facemasks and PPE offerings enhanced by their unique silver infused fibre technology.  These masks have become a top seller at CVS stores and other retail locations.  Boomer also offers face shields, coveralls and hand sanitizers.

Defend

The Company already vends a suite of immunity boosting botanical products and healthy living products and is excited to announce it is ready to launch a new suite of premium products enhanced with Boomer silver technology.

The Company plans to launch the following silver infused products and more to match existing consumer demand in the first six months of 2021:

  • Bedding
  • Socks
  • Yoga mats
  • Yoga clothing
  • T-shirts
  • Leggings
  • Underwear

Enhance

Through an exclusive partnership in Vietnam Boomer Holdings will launch Vietnamese instant coffee to the American Market.

Vietnamese coffee naturally has nearly twice the caffeine of popular instant coffees with a preferable flavour. Boomer believes it will open up an untapped market of consumer demand with its superior instant coffee stick packages.

“Vietnamese coffee is booming in Europe, Asia and across the globe however has yet to gain a significant foothold in America.” States CEO Mike Quaid. “It has typically been difficult for US based retailers to get a consistent, premium quality Vietnamese coffee supplier for the American Market.  Boomer Holdings has partnered with just such a supplier. We are certain that once the American consumer tries this new and superior version of instant coffee, the stars will align and they will buck their current coffee and get on the Boomer Coffee train.”

The Company is also launching a full line of instant serve packs including vitamin, workout, libido, sleep, calm, and immune powder mixes. These products will be excellent for e-commerce due to their ease of shipping.

An Enhanced Focus on E-Commerce

Now that the Company has an established foothold in traditional brick and mortar retail operations, it will focus on aggressively expanding its ecommerce business.

The Company’s goal is to add over 100 new products in 2021 and to expand our DTC database from over 200,000 to millions.

Many of the Boomer products are designed to create recurring residual revenue.

Boomer Holding’s E-Commerce division has the highest margin in the Company, with many products averaging 80% or above.

The lifetime value of a Boomer customer can often be in the thousands of dollars. The Company currently has online customers that have reordered over twenty times in the last year.

Boomer Holdings is forecasting E-Commerce revenue to grow to $66.4 million for the year ending January 2022.

Updated Fiscal Year Forecast

The Company expects sales to range from $90.50 to $115.5 million dollars in the current fiscal year, with operating profits ranging from $20.3 to $26.6 million dollars with e-commerce being the driving force for this year and the future.

“Boomer Holdings is already growing at a rate that would make many existing companies envious.” Said Mike Quaid. “We look forward to providing our shareholders with tremendous value in 2021 and years into the future”.

About Boomer Naturals

Boomer Naturals is a wholly-owned subsidiary of Boomer Holdings Inc., a publicly traded company (OTCQB: BOMH). Boomer Naturals is a full-service wellness company that provides products and services that enhance your well-being and increase your quality of life. Boomer Naturals’ products are available online at Boomerstore.com, BoomerNaturals.com, BoomerNaturalsWholesale.com, CVS.com. Boomer Naturals’ products are also available at the Boomer Naturals retail store, CVS retail locations, and resorts and golf shops across the country. For more information, please visit www.boomernaturals.com.

Forward Looking Statements

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future, except as required by securities laws. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company’s control, risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19), and those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”). There may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.

1 https://www.forbes.com/sites/andriacheng/2020/06/11/us-consumers-are-less-willing-to-buy-made-in-china-items-in-wake-of-coronavirus-pandemic-study/?sh=6e9f53116a75

Contact: Mike Quaid: mike@boomernaturals.com

SOURCE Boomer Naturals, Inc

Release – Ceapro Inc. (CRPOF)(CZO:CA) – Announces Successful Completion of Collaborative Research and Development Program with University of Alberta

Posted on by Admin


Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta

 

– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –

– New PGX-based products developed under the collaboration paves the way for commercial scale production of new chemical complexes and innovative delivery systems –

– Potential for applications in personal care, functional food, dietary supplement and pharmaceuticals –

– Findings to be presented at the upcoming 18 th European Meeting on Supercritical Fluids –

EDMONTON, Alberta, April 08, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of its long-term research project with Professor Dr. Feral Temelli at the University of Alberta (UofA). Based on the successful results of the project, Ceapro will expand the utilization of the PGX Technology and generate innovative high-value ingredients with a competitive advantage, targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals.

The collaborative project titled “ PGX technology for drying of biopolymers and their impregnation with bioactives ” was initiated in June 2017 and leveraged funding with the Collaborative Research and Development (CRD) grant project from the Natural Sciences and Engineering Research Council of Canada (NSERC). The goal of the project was to expand the array of PGX-processed polymers impregnated with bioactives based on a solid understanding of their behavior under the PGX processing conditions and the interactions between them.

“This project allowed for the screening of various compounds and the retention of the most promising ones with the best marketing potential. With these important findings, we have established an expanded PGX-based product pipeline further supporting the investment decision for the commercial scale up of the PGX Technology for the processing of oat beta glucan, yeast beta glucan and alginate. These first three products offer potential benefits either as stand-alone products or as carrier for other bioactives. We are very grateful to Professor Dr. Feral Temelli, her research team at the UofA, and Ceapro’s research team for the success in this extensive collaborative research project,” commented Mr. Gilles Gagnon, President and Chief Executive Officer of Ceapro.

Results from this NSERC-CRD project demonstrated for the first time that Ceapro’s PGX Technology could be used to not only dry and purify polysaccharides like beta glucan, but also proteins and peptides, which could then be impregnated with valuable bioactives. Additionally, by leveraging the PGX Technology, the research team was able to generate unique composites known as exfoliated nanocomposites, made of homogenously intertwined polymers (e.g. polysaccharides, proteins, enzymes and gums) with remarkable new properties. This project also greatly contributed to the development of new processing approaches using the PGX Technology, especially for the development of new delivery systems even making the dispersions of hydrophobic bioactives in water stable.

“Over the course of this project, significant inroads were made into a completely new and promising field – the simultaneous drying, purification and functionalization of proteins, peptides, and enzymes,” said Dr. Paul Moquin, Director Scientific Affairs and New Business Development at Ceapro. “Researchers made unique alginate-protein composites made of homogenously intertwined polymers with remarkable new properties. Although it is early to totally capture the full impact that such findings will have on the development of future products, we expect that it will be disruptive to many economic sectors.”

Considerable resources were deployed during this project to study and characterize the PGX material, novel composites, and new delivery systems. Among all the work that was conducted, enhanced release kinetics of these hydrophobic bioactives in simulated gastrointestinal conditions was demonstrated, which is an indication of their potential increased bioavailability that can lead to improved health benefits. Results allow the selection of the best polymer as the carrier to generate optimal delivery systems for targeted applications including functional food, dietary supplement, personal care, cosmetic and drug applications.

“We are very happy to successfully complete this very ambitious project, generating a lot of new information, and paving the way for new opportunities and future applications of the PGX Technology,” said Professor Dr. Feral Temelli from the Department of Agricultural, Food & Nutritional Science of the University of Alberta. “It was a major collaborative effort between our teams at the University of Alberta and Ceapro. Based on the training received at the UofA throughout this project, two of my team members were hired by Ceapro and it is wonderful that they continue to contribute to the growth of the PGX Technology. I really appreciate the financial support of NSERC-CRD program and Ceapro for this major project.”

As a result of this collaborative work, Ceapro has greatly expanded its portfolio of innovative bioactive ingredients and delivery systems, and has garnered international attention, both in the industrial sector and the scientific community. The Company expects additional findings from this project to be published in peer-reviewed journals and scientific conferences, including three abstract presentations that have been accepted at the 18 th European Meeting on Supercritical Fluids (EMSF) being held virtually May 4-6, 2021. One of the abstracts will be presented as a keynote address by Dr. Feral Temelli.

About Pressurized Gas eXpanded Liquid Technology (PGX)

Ceapro’s patented Pressurized Gas eXpanded (PGX) technology is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, fine-structured, open-porous polymer structures and novel biocomposites. PGX is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers. It can make ultra-light, highly porous polymer structures on a continuous basis, which is not possible using today’s conventional technologies. PGX was invented by Dr. Feral Temelli from the Department of Agricultural, Food & Nutritional Science of the University of Alberta (U of A) along with Dr. Bernhard Seifried, now Senior Director of Research and Technology at Ceapro. The license from U of A provides Ceapro with exclusive worldwide rights in all industrial applications.

About University of Alberta

The University of Alberta in Edmonton is one of Canada’s top teaching and research universities, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering, and health sciences. Home to more than 38,000 students and 15,000 faculty and staff, the university has an annual budget of $1.9 billion and attracts more than $500 million in sponsored research revenue. The U of A offers close to 900 rigorous undergraduate, graduate, and professional programs in 18 faculties on five campuses-including one rural and one francophone campus. The university has more than 275,000 alumni worldwide. The university and its people remain dedicated to the promise made in 1908 by founding President Henry Marshall Tory that knowledge shall be used for “uplifting the whole people.”

About Natural Sciences and Engineering Research Council of Canada (NSERC)

The NSERC, through grants, fellowships and scholarships, promotes and supports research and research training in the natural sciences and engineering to develop talent, generate discoveries, and support innovation in pursuit of economic and social outcomes for Canadians

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company’s website at www.ceapro.com .

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Source: Ceapro Inc.

Release – Boomer Holdings (BOMH) – Provides Shareholder Update and Q1 Guidance With New Revenue and Profit Forecasts

Posted on by Admin

 


Boomer Provides Shareholder Update and Q1 Guidance With New Revenue and Profit Forecasts

 

LAS VEGAS, April 8, 2021 /PRNewswire/ — Boomer Holdings, Inc. (“Boomer” or the “Company”) (OTCQB: BOMH), an innovative Consumer Products Company specializing in a large variety of premium quality wellness and everyday use products under the Boomer brand name.  The Company provided a shareholder update on the Company’s operations in conjunction with its change of its fiscal year end to January 31.

The Company had a record quarter ending October 31, 2020 with revenue of $28.8 million and operating profits of $7.9 million.  The Company plans to announce the audited year end January 31, 2021 financials by early May 2021.

Mike Quaid, CEO of Boomer Naturals said: “While we are extremely proud to report our results and the accomplishments of the Boomer Naturals team over the past year, we are more excited for the growth that we hope to come in 2021. Boomer Naturals has taken its meteoric success over the last year and reinvented itself.  We are at the beginning of what I believe to be one of the great growth stories of 2021.”

Studies show that consumers are less willing to buy ‘Made in China’ items in the wake of the Coronavirus pandemic, which we believe will help fuel growth as all Boomer products are made in Vietnam or the USA. 1

The Company is preparing the launch of its proprietary marketplace: boomerstore.com which will allow the Company to expand its offering to its loyal group of over 200,000 online customers while expanding its already significant retail sales footprint.

“The first quarter of 2021 for Boomer has been focused on preparation to service the expected demand Boomer has created for the rest of the year,” said Mr. Quaid. “We have deployed our capital in a strategic manner and stand ready to reap the benefits in Q2 and beyond.”  

Boomerstore.com will provide new and already established consumers with direct access to Boomer Naturals three pillars of wellness and everyday use products: Protect, Defend and Enhance.

Protect

Boomer Naturals is already well known for the best-in-class facemasks and PPE offerings enhanced by their unique silver infused fibre technology.  These masks have become a top seller at CVS stores and other retail locations.  Boomer also offers face shields, coveralls and hand sanitizers.

Defend

The Company already vends a suite of immunity boosting botanical products and healthy living products and is excited to announce it is ready to launch a new suite of premium products enhanced with Boomer silver technology.

The Company plans to launch the following silver infused products and more to match existing consumer demand in the first six months of 2021:

  • Bedding
  • Socks
  • Yoga mats
  • Yoga clothing
  • T-shirts
  • Leggings
  • Underwear

Enhance

Through an exclusive partnership in Vietnam Boomer Holdings will launch Vietnamese instant coffee to the American Market.

Vietnamese coffee naturally has nearly twice the caffeine of popular instant coffees with a preferable flavour. Boomer believes it will open up an untapped market of consumer demand with its superior instant coffee stick packages.

“Vietnamese coffee is booming in Europe, Asia and across the globe however has yet to gain a significant foothold in America.” States CEO Mike Quaid. “It has typically been difficult for US based retailers to get a consistent, premium quality Vietnamese coffee supplier for the American Market.  Boomer Holdings has partnered with just such a supplier. We are certain that once the American consumer tries this new and superior version of instant coffee, the stars will align and they will buck their current coffee and get on the Boomer Coffee train.”

The Company is also launching a full line of instant serve packs including vitamin, workout, libido, sleep, calm, and immune powder mixes. These products will be excellent for e-commerce due to their ease of shipping.

An Enhanced Focus on E-Commerce

Now that the Company has an established foothold in traditional brick and mortar retail operations, it will focus on aggressively expanding its ecommerce business.

The Company’s goal is to add over 100 new products in 2021 and to expand our DTC database from over 200,000 to millions.

Many of the Boomer products are designed to create recurring residual revenue.

Boomer Holding’s E-Commerce division has the highest margin in the Company, with many products averaging 80% or above.

The lifetime value of a Boomer customer can often be in the thousands of dollars. The Company currently has online customers that have reordered over twenty times in the last year.

Boomer Holdings is forecasting E-Commerce revenue to grow to $66.4 million for the year ending January 2022.

Updated Fiscal Year Forecast

The Company expects sales to range from $90.50 to $115.5 million dollars in the current fiscal year, with operating profits ranging from $20.3 to $26.6 million dollars with e-commerce being the driving force for this year and the future.

“Boomer Holdings is already growing at a rate that would make many existing companies envious.” Said Mike Quaid. “We look forward to providing our shareholders with tremendous value in 2021 and years into the future”.

About Boomer Naturals

Boomer Naturals is a wholly-owned subsidiary of Boomer Holdings Inc., a publicly traded company (OTCQB: BOMH). Boomer Naturals is a full-service wellness company that provides products and services that enhance your well-being and increase your quality of life. Boomer Naturals’ products are available online at Boomerstore.com, BoomerNaturals.com, BoomerNaturalsWholesale.com, CVS.com. Boomer Naturals’ products are also available at the Boomer Naturals retail store, CVS retail locations, and resorts and golf shops across the country. For more information, please visit www.boomernaturals.com.

Forward Looking Statements

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future, except as required by securities laws. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company’s control, risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19), and those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”). There may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.

1 https://www.forbes.com/sites/andriacheng/2020/06/11/us-consumers-are-less-willing-to-buy-made-in-china-items-in-wake-of-coronavirus-pandemic-study/?sh=6e9f53116a75

Contact: Mike Quaid: mike@boomernaturals.com

SOURCE Boomer Naturals, Inc

QuickChek – April 8, 2021

Posted on by Admin



CoreCivic Announces Upsizing and Pricing of $450 Million 8.25% Senior Notes Due 2026

CoreCivic Announces Proposed $400 Million Senior Notes Offering

Today’s research report from Joe Gomes, Senior Research Analyst at Noble Capital Markets

Research, News & Market Data on CoreCivic

Watch recent presentation from NobleCon17



Boomer Provides Shareholder Update and Q1 Guidance With New Revenue and Profit Forecasts

Boomer Holdings provided a shareholder update on the Company’s operations in conjunction with its change of its fiscal year end to January 31

News & Market Data on Boomer Holdings



Comtech Telecommunications Awarded $1.3 Million Contract Renewal with Tier-One Mobile Network Operator

Comtech Telecommunications announced that during Q3 2021, its Location Technologies group was awarded a $1.3 million contract renewal to support messaging services

Research, News & Market Data on Comtech

Watch recent presentation from NobleCon17



Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta

Ceapro Inc. announced the successful completion of its long-term research project with Professor Dr. Feral Temelli at the University of Alberta

Research, News & Market Data on Ceapro

Watch recent presentation from NobleCon17



electroCore Announces Top Line Results from SAVIOR-1 study

electroCore announced the top-line results from the SAVIOR-1 study in patients admitted to the hospital for treatment of COVID-19

Research, News & Market Data on electroCore



Silver production results for Q1 2021

Endeavour Silver reported 1,048,100 oz Silver and 11,109 oz Gold for 1.9 Million oz Silver Equivalents in Q1, 2021

Research, News & Market Data on Endeavour Silver

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Winners and Losers from the American Jobs Plan

Posted on by Admin

 


Potential Rocketships from the Proposed Infrastructure Plan (Plus Explosions)

On March 31, 2021, the White House released details of the American Jobs Plan (AJP), a $2.2 trillion eight-year plan to improve the infrastructure of the United States. While the program uses the term infrastructure loosely to include modernizing schools and childcare facilities and providing affordable housing, it is worth noting that the proposal includes $100 billion to upgrade the nation’s energy transmission industry. In support for this expenditure, the president cited a Department of Energy study that found that power outages cost the U.S. Economy up to $70 billion annually. The plan attacks many aspects of the current energy system and would have a dramatic impact on the energy and utility industries.  Chief among the proposed changes are:

  • Establish a new Grid Deployment Authority at the DOE. The agency would allow for better leverage of existing rights of way and help finance new power transmission lines.
  • Provide for tax credits, clean energy procurement by the federal government, and grant support to state, local and tribal governments to improve energy efficiency and reach 100% carbon-free power by 2035.
  • Provide investment tax credits for transmission lines would help build out 20 gigawatts (GW) of high-voltage capacity lines and support the building of clean energy generation. The tax credits would extend current credits, phasing them out over a ten-year period.
  • Establish a “Green Bank” which would have the authority to invest $27 billion alongside the private sector to speed the deployment of new energy technologies.
  • Make $174 billion of investments in the electric vehicle market, giving consumers point of sale rebates and tax incentives to buy American-made EVs. It also gives incentives to state and local governments and the private sector to build a national network of 500,000 EV charging stations, up from current levels of 42,000.
  • Purchase clean energy for all government buildings and many government vehicles. The plan would electrify the US Postal Service vehicles.

Winners

Electric Utilities: The electric utility industry seems to be a clear winner from the AJP. Through subsidies and tax credits, they will expand their rate base by upgrading and building new transmission lines at a faster rate. They will also benefit from increased electric flow associated with a shift towards electric vehicles. We believe the benefits of increased demand will more than offset the negative effects of increased regulation.

Renewable Energy Generators: The extension of tax credits for clean energy manufacturing will benefit companies involved in the generation of renewable energy. These include solar, hydro, biofuel, and other forms of generation. Distributed generation companies will benefit from extended tax credits and increased awareness of their products. Companies involved in the research and development of generation and storage will benefit from direct government investments.

Nuclear Manufacturers and Uranium Producers: The shift towards zero-carbon power generations may spur a new era of investments in nuclear generation. Unless power storage capabilities are improved, renewable power sources such as wind and solar will continue to require a solid baseload of generation from other sources. In the last few years, technological improvements have increased the viability of small nuclear reactors that are safer and more efficient than traditional nuclear reactors. Building new nuclear reactors would have a direct positive effect on the uranium industry, which has been depressed ever since the Fukushima disaster in 2011.

Losers

Carbon-based fuels such as coal and oil: The AJP would accelerate the shift towards clean energy to the detriment of traditional carbon-based fuels such as coal and oil. Decreased demand for gasoline resulting from a shift towards electric vehicles would lessen the demand for oil. The building of an improved electric transmission grid would support the development of wind and solar generation and mean less coal and oil-based generation. Forcing utilities to wean themselves off carbon-emitting sources by 2035 would put many coal and oil generation plants out of commission before the end of their useful life.

Take-Away

A proposal is just a proposal, and the finer details of any infrastructure plan will need to be ironed out. That understood, from an investor’s standpoint, it is clear that the president intends to push support of clean energy initiatives. The expected success would benefit carbon-free companies and hurt carbon-based companies. Coal and oil producers will not go away but demand growth for their fuels will be less. On the other hand, demand for clean energy fuels will increase. How quickly demand shift to green fuels will depend on the ultimate shape of whatever infrastructure plan is passed by government.

Suggested Reading:

How Does Uranium Fit Into the Energy Landscape?

Is the Price of Uranium Rising?



Will Solar Panels Continue to be Subsidized?

Who Benefits from the American Jobs Plan?

 

 

Sources:

https://www.whitehouse.gov/briefing-room/statements-releases/2021/03/31/fact-sheet-the-american-jobs-plan/, The White House, March 31, 2021

https://www.csis.org/analysis/american-jobs-plan-gets-serious-about-infrastructure-and-climate-change, Lachlan Carey, Center For Strategic & International Studies, April 2, 2021

https://www.wri.org/blog/2021/04/american-jobs-plan-climate-jobs-us, World Resources Institute, April 1, 2021

https://www.washingtonpost.com/us-policy/2021/03/31/biden-infrastructure-climate-plan/, Jeff Stein, Juliet Eilperin, Michael Laris and Tony Romm, Washington Post, April 1, 2021

Photo: NASA Capture of Antares Rocket October 2014 just before Explosion

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – electroCore Inc. (ECOR) – Announces Top Line Results From SAVIOR-1 Study

Posted on by Admin


electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

 

ROCKAWAY, NJ, 
April 08, 2021 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the top-line results from the SAVIOR-1 study, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire in patients admitted to the hospital for treatment of COVID-19 between 
April 2020 and 
February 2021. This study was an investigator-initiated trial conducted at the Hospital Clínico Universitario de 
Valencia, Spain.

The SAVIOR-1 study enrolled 110 patients over 18 years of age. A total of 97 patients (47 treatment subjects and 50 control subjects) provided baseline demographic and medical history data. The study was designed to evaluate the safety and feasibility of nVNS in addition to the current standard of care in patients hospitalized with active SARS-CoV-2 infection. This pilot study also assessed the incidence of relevant clinical events and changes in blood chemistry between the group treated with nVNS in addition to the standard of care at the time of admission, compared with standard of care alone.

The patients’ clinical and biochemical endpoints were measured over their first five days of therapy and the adjusted means were compared. It was noted that the post-randomized assessment of severity of condition resulted in a 3.5 to 1 bias with more severe patients in the treatment arm.  With respect to the clinical endpoint of oxygen saturation, the nVNS treated group showed a modest, but not significant improvement. Among the biomarkers evaluated, the adjusted mean decrease in C-Reactive Protein (CRP) from baseline was significantly greater in the nVNS treated group (-59.08 vs. -27.83; p<0.01). Trends toward significance were also observed for decreases in the treatment group for procalcitonin (-0.11 vs. -0.05; p= 0.07) and d-dimer (-277.53 vs. 1264.37; p=0.08). Increased levels of CRP, procalcitonin and d-dimer have all been reported to be associated with more severe disease. The lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms. Other biochemical measures also favored the treatment group but did not achieve significance.

nVNS was well tolerated with no major device related adverse events and the therapy was administered three times daily on the majority of patients as outlined in the study protocol. Full data from the study, including cytokine levels which are pending final lab results, will be submitted to a peer reviewed journal later this year.

The principal investigator of the study, Dr.  Carlos Tornero, Head of the 
Department of Anesthesiology, Resuscitation and Pain Therapeutics of the Hospital Clínico Universitario de 
Valencia, Spain, commented, “We are very pleased to have successfully completed the SAVIOR-1 study despite the challenges of executing a trial of a novel neuromodulation treatment during  a pandemic, and the rapidly changing standard of care in COVID-19 patients. These top line results suggest that nVNS may contribute to our efforts in combating the on-going disease process through a more rapid recovery in some of the biomarkers that are typically associated with a more severe prognosis.”

“The ability of nVNS to potentially affect the progression of COVID-19 in these hospitalized patients is encouraging.” said Dr.  Peter Staats, Chief Medical Officer of electroCore. “As the pandemic evolves, we believe that nVNS could be a viable treatment for patients to possibly help decrease their symptoms early in the disease. Although a minority of the subjects in the study were classified as severe, the randomization process apportioned more than 75% of the severe population into the treatment arm, which may have impacted the top line results.”

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM
gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric
    • Patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

The U.S. FDA has cleared the gammaCore Sapphire CV device under an emergency use authorization for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved pharmacologic therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, using noninvasive vagus nerve stimulation (nVNS) on either side of the patient’s neck.

gammaCore Sapphire CV has been authorized only for the duration of the statement that circumstances exist that warrant authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbbb-3(b)(1), until the authorization is terminated or revoked.

More information can be found at:

Letter of authorization: https://www.fda.gov/media/139967/download

Fact sheet for healthcare workers: https://www.fda.gov/media/139968/download

Patient information sheet: https://www.fda.gov/media/139969/download

Instructions for use of gammaCore: https://www.fda.gov/media/139970/download

Forward-looking statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the 
SEC, available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
ECOR@cg.capital

or

Media Contact:
Summer Diaz
electroCore
973-290-0097
summer.diaz@electrocore.com

Release – Endeavor Silver (EXK) – Produces 1,048,100 oz Silver and 11,109 oz Gold for 1.9 Million oz Silver Equivalents in Q1 2021

Posted on by Admin

 


Endeavour Silver Produces 1,048,100 oz Silver and 11,109 oz Gold for 1.9 Million oz Silver Equivalents in Q1, 2021

 

VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) —
Endeavour Silver Corp. (TSX: EDR, NYSE: EXK) reports production of 1,048,100 silver ounces (oz) and 11,109 gold oz in Q1, 2021, for silver equivalent (AgEq) production of 1.9 million oz at an 80:1 silver:gold ratio. Silver production increased 22% and gold production increased 31% compared to Q1, 2020, due primarily to higher ore grades mined and processed.

2021 First Quarter Highlights

  • Consolidated
    Production on Plan:     Silver equivalent production at each mine is on track to meet or exceed 2021 production plans.
  • Guanacevi
    Production on Plan:     Higher silver and gold grades were partly offset by slightly lower throughput than planned during the quarter.
  • Bolanitos Ahead of Plan: Processed tonnes, gold grade and gold recoveries are ahead of plan, partly offset by slightly lower silver grades and recoveries compared to plan.
  • El Compas Ahead of Plan: Processed tonnes, and gold grade are ahead of plan, partly offset by slightly lower silver grade and lower gold recoveries compared to plan.
  • Metal Sales and
    Inventories:     Sold 623,379 oz silver and 10,663 oz gold, held 523,235 oz silver and 1,123 oz gold of bullion inventory and 6,582 oz silver and 566 oz gold in concentrate inventory. Management withheld metal from sale during the price correction over last two weeks of March and plans to sell the withheld metal inventory in anticipation of a precious metal prices rebound in Q2, 2021.
  • Signed Definitive
    Agreement to Sell the El Cubo Assets:     Advanced sale of the El Cubo mine in Guanajuato, Mexico to VanGold Mining Corp for $15 million in cash and share payments, with up to $3 million in contingent payments. The transaction is anticipated to close in April 2021.
  • Shares Included in Two Major Indices: The Company’s common shares were added to the S&P/TSX Composite Index and the NYSE Arca Gold Miners Index (GDX ETF) in March.
  • Announced Management Succession Plan: Bradford Cooke plans to step down as CEO and assume the role of Executive Chair of the Company following the AGM on May 12, 2021. Dan Dickson has been nominated to the role of CEO and Christine West has been nominated to become the CFO. Both Mr. Dickson and Ms. West have been key members of management for over 13 years and will lead the Company into its next phase of growth.

Bradford Cooke, Endeavour CEO, commented, “It is gratifying to see the Company firing on all cylinders, with the mining operations meeting or exceeding expectations and the development team advancing the Terronera project to drive the next phase of growth. I will look forward to supporting Dan and Christine in their new roles as they build a bigger and better Company.”

Mine Operations

Consolidated silver and gold production were both higher in Q1, 2021 compared to Q1, 2020 due to a significant increase in ore grades at Guanacevi and improved throughput and ore grades at Bolanitos.

Guanacevi silver and gold grades were higher compared to Q1, 2020 and well above plan. In February, unusually cold weather in northern Mexico resulted in power curtailments effecting mine and process plant production over a three-day period. In March, throughput was lower than initially planned as the refurbishment of the tailings filter presses impacted daily throughput. The plant throughput is expected to return to its 1200 tonnes per day capacity in April. Stockpiled ore inventory increased during the quarter as the mine output was on plan. With the higher metal prices, supplies of local third-party ores continued to supplement mine production, amounting to 10% of quarterly throughput, and contributed to the higher ore grades. Ore grades are expected to revert to plan in Q2, 2021 and for the remainder of the year.

Bolanitos and El Compas processed tonnes, and gold grade were all higher compared to Q1, 2020, partly offset by lower silver grades and both mines are slightly ahead of planned production. Settlement of El Compas concentrates resulted in lower recoveries during the quarter.

COVID-19 pandemic remains prevalent in Mexico, and at the Company’s business locations, process and protocols remain in place to ensure staff and workers as well as our communities remain as safe as possible.

Production Highlights for Q1, 2021

Q1 2021 Highlights

Three Months Ended March 31

2021

2020

% Change

Throughput (tonnes)

209,453

199,327

5%

Silver ounces produced

1,048,100

857,659

22%

Gold ounces produced

11,109

8,476

31%

Payable silver ounces produced

1,036,710

849,791

22%

Payable gold ounces produced

10,894

8,320

31%

Silver equivalent ounces produced(1)

1,936,820

1,535,739

26%

Silver ounces sold

623,379

665,500

(6%)

Gold ounces sold

10,663

7,454

43%

(1)    Silver
equivalent ounces calculated using 80 :1 ratio .

Production Tables for First Quarter, 2021 by Mine

Production

Tonnes

Tonnes

Grade

Grade

Recovery

Recovery

Silver

Gold

by
mine

Produced

per day

Ag gpt ( 1)

Au gpt ( 1)

Ag %

Au %

Oz

Oz

Guanaceví

88,632

974

369

1.05

87.3%

91.7%

918,217

2,743

Bolañitos

97,692

1,074

38

2.15

89.0%

91.5%

106,227

6,182

El Compas

23,129

254

47

4.12

67.7%

71.3%

23,656

2,184

Consolidated

209,453

2,302

179

1.90

86.9%

86.7%

1,048,100

11,109

(1)  gpt = grams per tonne

Release of First Quarter,
2021 Financial Results and Conference Call

The 2021 First Quarter Financial Results will be released before market on Tuesday, May 11, 2021 and a telephone conference call will be held the same day at 9:00am PT (12:00pm ET). To participate in the conference call, please dial the numbers below. No pass code is necessary.

Toll-free in Canada and the US: 1-800-319-4610
Local Vancouver: 604-638-5340
Outside of Canada and the US: +604-638-5340

A replay of the conference call will be available by dialing 1-800-319-6413 in Canada and the US (toll-free) or +604-638-9010 outside of Canada and the US. The required pass code is 6594#. The audio replay and a written transcript will be available on the Company’s website at www.edrsilver.com under the Investor Relations, Events section.

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer.  Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact Information:
Galina Meleger, Director, Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: gmeleger@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding the timing of suspension of
mining operations, Endeavour’s anticipated performance in 2021, including
production forecasts, cost estimates and metal price estimates, and the timing
and results of mine expansion and development and receipt of various permits.
The Company does not intend to and does not assume any obligation to update
such forward-looking statements or information, other than as required by
applicable law.

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, performance
or achievements of Endeavour and its operations to be materially different from
those expressed or implied by such statements. Such factors include, among
others, uncertainty of the ultimate impact of the COVID 19 pandemic on
operations, changes in national and local governments, legislation, taxation,
controls, regulations and political or economic developments in Canada and
Mexico; operating or technical difficulties in mineral exploration, development
and mining activities; risks and hazards of mineral exploration, development
and mining; metal prices; the speculative nature of mineral exploration and
development, risks in obtaining necessary licenses and permits, and challenges
to the Company’s title to properties; as well as those factors described in the
section “risk factors” contained in the Company’s most recent form 40F/Annual
Information Form filed with the S.E.C. and Canadian securities regulatory
authorities.

Forward-looking statements
are based on assumptions management believes to be reasonable, including but
not limited to: the continued operation of the Company’s mining operations ,the
impact of the COVID 19 pandemic on mining operations in Mexico generally, and
the Company’s operations specifically, no material adverse change in the market
price of commodities, mining operations will operate and the mining products
will be completed in accordance with management’s expectations and achieve
their stated production outcomes, resource and reserve estimates, metal prices,
and such other assumptions and factors as set out herein. Although the Company
has attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or
information, there may be other factors that cause results to be materially different
from those anticipated, described, estimated, assessed or intended. There can
be no assurance that any forward-looking statements or information will prove
to be accurate as actual results and future events could differ materially from
those anticipated in such statements or information. Accordingly, readers
should not place undue reliance on forward-looking statements or information.

Source: Endeavour Silver Corporation

The GEO Group, Inc. (GEO) – Suspends Dividend Evaluating Corporate Structure

Posted on by Admin

Thursday, April 08, 2021

The GEO Group, Inc. (GEO)
Suspends Dividend; Evaluating Corporate Structure

With over 94,000 beds owned, leased or managed across its business lines and serving over 260,000 people daily, GEO is a leading provider of mission critical real estate to its governmental partners. The Company is the first fully integrated equity REIT specializing in the design, financing, development, and operation of secure facilities, processing centers, and community reentry centers in the U.S., Australia, South Africa, and the U.K.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Dividend Suspension. In a not so surprising move, GEO Group announced it is immediately suspending the quarterly dividend. The suspension eliminates approximately $30 million in quarterly dividend payments. Management expects to use the dividend savings and lowered capital expenditure plans to repay a minimum of $125-$150 million of net debt in 2021.

    Evaluating Corporate Structure.  The Company also announced it is undertaking an evaluation of the current REIT structure. The evaluation is expected to be completed in the fourth quarter of 2021. Obviously, uncertainty swirling around the current operating and the prosed increase in the corporate tax rate will both be important considerations …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – A Win on Marsh Creation in Louisiana

Posted on by Admin

Thursday, April 08, 2021

Great Lakes Dredge & Dock (GLDD)
A Win on Marsh Creation in Louisiana

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another win by a slight margin in Louisiana. Bids were opened by the Coastal Protection & Restoration Authority (CPRA) late yesterday afternoon on the Golden Triangle Marsh Creation Project (PO-0163) in Louisiana. GLDD was the apparent low bidder at $32.4 million, with Weeks Marine closely behind at $33.7 million and Manson lagging with the highest bid at $77.1 million. A total of seven companies bid, and the low end of the bidding range was below the designer’s estimate was $38.21 million.

    Solid dredging outlook with backlog at $559 million and potential infrastructure spending stimulus could create a tailwind.  Another state project in Louisiana is out for bid now; Bids will be opened on the Lake Borgne Marsh Creation Project – Increment One (PO-0180) in St. Bernard Parish bids on April 21st …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.